ML 141 CDC42 Inhibition for S. aureus Intracellular Persistence
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bacterial infections, particularly those caused by Staphylococcus aureus, face challenges due to antibiotic resistance and the ability of bacteria to persist intracellularly, leading to chronic infections and evasion of antibiotics and immune cells.
Innovation Solution
The compound ML 141 specifically inhibits CDC42, a small GTPase involved in bacterial invasion, by binding directly to it and disrupting its GTP-binding activity, thereby reducing host cell invasion and intracellular persistence of S. aureus.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotics are used to treat bacterial infections, then bacterial growth is inhibited, but antibiotic resistance develops and intracellular persistence occurs
Solution Approach 1:
The patent extracts and targets the specific molecular mechanism (CDC42 GTPase) that bacteria exploit for intracellular invasion and persistence. By removing or blocking this specific function rather than broadly inhibiting bacterial growth, the treatment prevents intracellular persistence without selecting for traditional antibiotic resistance mechanisms.
Solution Approach 2:
The compound ML 141 acts as an intermediary that blocks the interaction between bacterial pathogens and host cell CDC42 GTPase. This mediator prevents the bacterial manipulation of host cell invasion pathways without directly killing bacteria, thereby avoiding resistance development while preventing intracellular persistence.
2Reliability
If statins are used to inhibit CDC42 through mevalonate pathway, then CDC42 function is reduced, but the mechanism is indirect and non-specific
Solution Approach 1:
The patent replaces the indirect biochemical pathway inhibition (mevalonate pathway) with direct molecular binding to CDC42. This substitution changes the mechanism from metabolic interference to direct target engagement, achieving the same functional outcome with greater specificity and simpler mechanism.
Solution Approach 2:
The compound ML 141 changes the binding parameters by directly interacting with CDC42 at its GTP-binding site rather than affecting upstream metabolic parameters. This parameter change from indirect metabolic control to direct target binding achieves more specific and reliable CDC42 inhibition.
3Reliability
If broad-spectrum antibiotics are used to eliminate bacterial infections, then infection is reduced, but normal flora is disrupted and chronic infection persists
Solution Approach 1:
The patent applies local quality by targeting the specific molecular interaction (CDC42-GTPase) that is locally exploited by pathogens for intracellular invasion. This localized targeting at the molecular level spares normal physiological processes and flora while effectively preventing infection persistence.
Solution Approach 2:
Instead of killing bacteria directly (traditional approach), the patent inverts the strategy by blocking the host cell mechanism (CDC42) that bacteria exploit for invasion. This inverted approach prevents bacterial persistence without affecting bacterial viability or normal flora.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
ML 141 effectively decreases the invasion and persistence of S. aureus in host cells, potentially limiting chronic infection and initiating pleiotropic effects by interrupting the PI3K signaling pathway, with preliminary data indicating its potential as a first-in-class adjunctive therapeutic.
Implementation Method 1
ML 141 binds directly to CDC42 with a high degree of specificity for this small-GTPase. ML 141 inhibits GTP-binding at the activation site of CDC42.
Implementation Method 2
The isoprenoid intermediates farnesyl pyrophosphate and geranylgeranyl pyrophosphate provide membrane anchoring and protein-protein interactions for CaaX-motif containing proteins that include CDC42.
Data Source
AI summary
The present disclosure relates to molecules which function as selective modulators (i.e., inhibitors and agonists) of the Ras-homologous (Rho) family of small GTPases and, in particular, CDC42 GTPase, and their use to treat bacterial infection including systemic infection from sources such as Staphylococcus aureus.